AZD2796 / AstraZeneca - LARVOL DELTA

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity. (PubMed, J Immunother Cancer) - "These findings support the potential of AZD2796 as an anti-cancer therapy, with the ability to synergize with T-cell-based therapeutics."

Journal • Oncology • Solid Tumor • CD34 • CD40LG • LILRB2

AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity (SITC 2023) - "Conclusions AZD2796 is a high affinity anti-LILRB2 monoclonal antibody that promotes pro-inflammatory responses by macrophages and enhances anti-tumor activity of T cells. Our pre-clinical data support the potential of AZD2796 as an anti-cancer therapy with opportunities to combine with T-cell-based therapeutics."

Checkpoint inhibition • Lung Cancer • Melanoma • Oncology • Solid Tumor • CD40LG • TNFA